Lu AA24530
From Self-sufficiency
Revision as of 16:23, 29 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Systematic (IUPAC) name | |
---|---|
? | |
Identifiers | |
CAS Number | ? |
ATC code | none |
PubChem | CID ? |
Chemical data | |
Formula | ? |
Molar mass | ? |
Lu AA24530 is a antidepressant currently under development by Lundbeck and Takeda for the treatment of major depressive disorder.[1][2] As of March 2010 it is in phase III clinical trials.[3] Lu AA24530 acts as a monoamine reuptake inhibitor (reportedly serotonin according to one source), 5-HT2C receptor antagonist, and 5-HT3 receptor antagonist.[4][5] An NDA is not expected to be submitted to the FDA until at least 2012.[1]
See also
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
- Lu AA24530 shows positive results in major depressive disorder phase II study
- Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical trials with Lu AA21004 and Lu AA24530
GABAA PAMs |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
α2δ VDCC Blockers | |||||||||||
5-HT1A Agonists | |||||||||||
H1 Antagonists | Diphenylmethanes: Captodiame • Hydroxyzine; Others: Brompheniramine • Chlorpheniramine • Pheniramine | ||||||||||
CRH1 Antagonists | |||||||||||
NK2 Antagonists | |||||||||||
MCH1 antagonists | |||||||||||
mGluR2/3 Agonists | |||||||||||
mGluR5 NAMs | |||||||||||
TSPO agonists | |||||||||||
σ1 agonists | |||||||||||
Others | Benzoctamine • Carbetocin • Demoxytocin • Mephenoxalone • Mepiprazole • Oxanamide • Oxytocin • Promoxolane • Tofisopam • Trimetozine • WAY-267,464 | ||||||||||
|
| |||||||||||||||
| |||||||||||||||
| |||||||||||||||
| |||||||||||||||
| |||||||||||||||
| |||||||||||||||
|
35px | This drug article relating to the nervous system is a stub. You can help ssf by expanding it. |
- ↑ 1.0 1.1 "Development programme - Lundbeck".
- ↑ "Search of: Lu AA24530 - List Results - ClinicalTrials.gov".
- ↑ "Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical trials with Lu AA21004 and Lu AA24530 (March 3, 2010) | 2010 | Newsroom | Takeda Pharmaceutical Company Limited".
- ↑ "Lu AA24530 shows positive results in major depressive disorder phase II study - FierceBiotech".
- ↑ "Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net".
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Lu_AA24530&oldid=22777"
Categories:
- Pages with script errors
- Infobox drug articles without a structure image
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Chemical articles using a fixed chemical formula
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Antidepressants
- Pages with broken file links
- Nervous system drug stubs
- 2Fix